Item 1.01. Entry into a Material Definitive Agreement

On June 24, 2020, Abbott Laboratories ("Abbott") completed the public offering and issuance of $1,300,000,000 aggregate principal amount of senior notes, consisting of $650,000,000 aggregate principal amount of its 1.150% Notes due 2028 (the "2028 Notes") and $650,000,000 aggregate principal amount of its 1.400% Notes due 2030 (the "2030 Notes" and together with the 2028 Notes, the "Notes").

The Notes were sold pursuant to a pricing agreement, dated June 22, 2020 (the "Pricing Agreement"), among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein. The Notes were issued pursuant to the Prospectus Supplement, dated June 22, 2020, and filed with the Securities and Exchange Commission (the "SEC") on June 23, 2020, and the Prospectus, dated June 22, 2020, filed as part of the shelf registration statement (File No. 333-239333) that became effective under the Securities Act of 1933, as amended, when filed with the SEC on June 22, 2020.

Abbott may redeem some or all of the Notes of each series at any time at its option, in whole or from time to time in part, at the redemption prices specified in the applicable Note. Abbott intends to use the net proceeds from the Notes offering for general corporate purposes, which may include, without limitation, the repayment of indebtedness.

Please refer to the Prospectus Supplement, dated June 22, 2020, for additional information regarding the Notes offering and the terms and conditions of the Notes. The foregoing summary of the Notes does not purport to be complete and is qualified in its entirety by reference to the full text of (i) the Indenture filed as Exhibit 4.1 hereto? and (ii) the Officers' Certificate filed as Exhibit 4.2 hereto.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information included in Item 1.01 of this report is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





Exhibit No.                                  Description
  1.1             Pricing Agreement
  4.1             Indenture, dated as of March 10, 2015, between Abbott Laboratories
                and U.S. Bank National Association (including form of security)
                (previously filed as an exhibit to Abbott's Current Report on Form
                8-K, filed with the SEC on March 10, 2015)
                  Officers' Certificate Pursuant to Sections 3.1 and 3.3 of the
                Indenture with respect to 1.150% Notes due 2028 and 1.400% Notes due
  4.2           2030
                  Form of 1.150% Notes due 2028 (included in Exhibit 4.2 of this
  4.3           Current Report on Form 8-K)
                  Form of 1.400% Notes due 2030 (included in Exhibit 4.2 of this
  4.4           Current Report on Form 8-K)
  5.1             Opinion of Wachtell, Lipton, Rosen & Katz
                  Consent of Wachtell, Lipton, Rosen & Katz (included in Exhibit 5.1
  23.1          of this Current Report on Form 8-K)
                Cover Page Interactive Data File (the cover page XBRL tags are
104             embedded in the Inline XBRL document)




                                       2

© Edgar Online, source Glimpses